OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The companies have entered into an agreement for the technology transfer and clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, in Europe.
Mustang Bio, a US-based clinical-stage biopharmaceutical company, and Minaris Regenerative Medicine, a cell and gene therapy contract development and manufacturing organization, announced on Nov. 23, 2020 that they have entered into an agreement for the technology transfer and clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease, in Europe.
Through the agreement, Minaris will initiate the technology transfer of the manufacturing and analytical processes and will integrate it into the European regulatory environment for manufacturing at its Ottobrunn, Germany site in order to supply clinical trials in Europe, a Mustang press release said.
“We look forward to a productive and successful partnership with Mustang where Minaris will be able to support them with our extensive experience in the clinical and commercial manufacturing of autologous gene therapies,” said Dusan Kosijer, managing director of Minaris, in the press release. “We are eager to work together with Mustang in the fight against this devastating disease.”
“This agreement with Minaris is an important step in supporting expansion of our MB-107 pivotal clinical trial into Europe,” said Manuel Litchman, MD, president and CEO of Mustang, in the press release. “We look forward to working with Minaris to grow our geographic footprint and bring this potential life-saving therapy to XSCID patients in need internationally.”